DexCom Inc. ($DXCM) Stock Forecast: Down 5.9% Today

What is DexCom Inc.?

DexCom Inc. (DXCM) operates in the medical device industry, specializing in continuous glucose monitoring systems for diabetes management. The company witnessed a notable downturn in the market today.

Why is DexCom Inc. going down?

DXCM stock is down 5.9% on Mar 27, 2026 19:06

• DXCM's stock price saw a considerable decrease in line with major indices like the S&P 500 and Dow Jones Industrial Average. This decline was influenced by rising uncertainties related to the U.S.-Iran conflict and impending policy decisions by the Trump administration.
• Despite DXCM exhibiting robust Year-over-Year EBITDA Growth of 52.52% and being deemed significantly undervalued, some investors may have exercised caution due to certain warning signals identified in the analysis.
• The recent disclosure by Vanguard Group, revealing no holdings of DXCM common stock subsequent to an internal reshuffling, may have further dampened investor sentiment towards the company.
• DXCM's underperformance in comparison to its competitors on Thursday and the conclusion of a two-day positive streak could have also played a role in the stock's downward trajectory, particularly amid the widespread market declines observed.

DXCM Price Chart

DXCM Technical Analysis

DXCM News

Align Technology, QuidelOrtho, DexCom, Insulet, and Omnicell Shares Are Falling, What You Need To Know

Several major stock indices, including the S&P 500 and Dow Jones Industrial Average, declined today due to escalating uncertainty surrounding the U.S.-Iran conflict and Trump administration policy deadlines, causing significant drops in various company shares. Specifically, Align Technology, QuidelOrtho, DexCom, Insulet, and Omnicell experienced notable share price decreases. The market's negative reaction to unpredictability was also reflected in a dip in consumer confidence, though such price drops can sometimes present buying opportunities for high-quality stocks.

https://markets.financialcontent.com/stocks/article/stockstory-2026-3-27-align-technology-quidelortho-dexcom-insulet-and-omnicell-shares-are-falling-what-you-need-to-know

DEXCOM YoY EBITDA Growth: 52.52% | Significantly Undervalued

This article analyzes DexCom Inc. (DXCM), highlighting its Year-over-Year EBITDA Growth of 52.52% as of December 2025. GuruFocus assesses DXCM with a GF Score of 91/100 and a GF Value of $108.11, indicating it is significantly undervalued compared to its current price of $62.83. Investors are cautioned to review three warning signs despite the positive growth and valuation.

https://www.gurufocus.com/term/growth_per_share_ebitda/NAS:DXCM

Vanguard (DXCM) amendment shows 0 shares after internal realignment

The Vanguard Group filed an amended 13G stating it beneficially owns 0 shares of Dexcom Inc (DXCM) common stock, representing 0% of the class. This change is due to an internal realignment effective January 12, 2026, under SEC Release No. 34-39538, where certain Vanguard subsidiaries will now report beneficial ownership separately. The amendment clarifies that Vanguard itself no longer has, or is deemed to have, beneficial ownership over these securities, with individual subsidiaries expected to report their holdings disaggregated.

https://www.stocktitan.net/sec-filings/DXCM/schedule-13g-a-dexcom-inc-amended-passive-investment-disclosure-be429cd8ce0a.html

DexCom Inc. stock underperforms Thursday when compared to competitors

DexCom Inc. (DXCM) stock fell 1.12% to $66.09 on Thursday, underperforming the broader market. This drop ended a two-day winning streak, as the S&P 500 Index and Dow Jones Industrial Average also experienced significant declines.

https://www.marketwatch.com/data-news/dexcom-inc-stock-underperforms-thursday-when-compared-to-competitors-995b3467-25a40c5b5557?mod=mw_quote_news&gaa_at=eafs&gaa_n=AWEtsqcPTryjwxKKXBPXv-1OuJt2MmpC09TF-bjXpEcWNbvDh_zL66bC3H48&gaa_ts=69c60d08&gaa_sig=C1Iu-3mGM66_0-tP4Zo5CTkclKHkQaw8h_jmorbLvbvmgctNAnuvQ10Oq6F-S0p_9VxjG1kzCsHCebgi44rmwA%3D%3D

Abbott Laboratories stock faces pipeline scrutiny amid diagnostics slowdown in Q1 2026

Abbott Laboratories is experiencing a slowdown in its core diagnostics segment, leading to investor scrutiny despite continued strong performance from its FreeStyle Libre diabetes care franchise and structural heart devices. The company's stock is testing key support levels as investor focus shifts from post-pandemic growth to sustainable organic drivers and the resilience of its established businesses like nutritionals. Challenges include moderating Libre growth in some markets, regulatory hurdles, and persistent diagnostics weakness, though the company's defensive profile and dividend history offer stability.

https://www.ad-hoc-news.de/boerse/news/ueberblick/abbott-laboratories-stock-faces-pipeline-scrutiny-amid-diagnostics/68992119

Trending Today

DexCom Inc. Price History

03.01.2026 - DXCM Stock was down 1.8%

• The decline in DXCM stock value could be linked to investors selling off their shares to secure profits following a period of substantial growth and optimistic forecasts for 2026.
• The recent change in leadership, marked by the appointment of new CEO, Jake Leach, may have prompted some uncertainty among investors, leading to selling pressure.
• Despite Peterson Wealth Services increasing their ownership in DXCM, the mixed activity among company insiders and the general market sentiment may have influenced the downward trend.
• The upcoming earnings reports from Diodes (DIOD) and Universal Technical Institute (UTI) are potential factors impacting investor confidence in the healthcare sector, contributing to the negative pressure on DXCM stock.

05.00.2026 - DXCM Stock was up 2.8%

• The bullish movement in DXCM stock today can be attributed to the company's position at an inflection point in the competitive glucose-monitoring market, with positive sentiment from analysts on its future prospects.
• Recent insider transactions, including some purchases at lower prices, suggest continued long-term confidence in DXCM despite short-term valuation concerns, contributing to the positive momentum.
• The company's innovative products and favorable regulatory environment are likely driving investor optimism and contributing to the stock's strong performance in today's trading session.

12.00.2026 - DXCM Stock was up 5.3%

• DexCom's stock had a notable bullish trend, propelled by robust preliminary Q4 results that surpassed revenue expectations and demonstrated significant growth in both domestic and international markets.
• The introduction of DexCom's G7 15-Day sensor and the FDA approval for Smart Basal technology have been key factors in fostering positive market sentiment, revealing a high demand for the company's advanced products.
• Analysts at Morgan Stanley maintained an Overweight rating for DexCom, pointing to the strong Q4 results and the appointment of a new CEO as favorable catalysts for the company's future growth.
• While there are varied analyst opinions on DexCom's valuation, the general market sentiment remains optimistic, with investors looking forward to the company's sustained revenue growth, enhanced margins, and expansion strategies for 2026.

12.00.2026 - DXCM Stock was up 5.1%

• Dexcom experienced a strong bullish movement recently due to several positive factors:
• The fourth-quarter revenue surpassed expectations, mainly due to the successful launch of the G7 15-Day sensor, showcasing the company's innovation and responsiveness to market needs.
• The appointment of a new President and CEO, Jake Leach, coupled with plans to introduce an AI-enabled Stelo app, reflects a strategic shift towards advanced technology in diabetes management.
• Analysts have expressed optimistic views on Dexcom's performance for 2026, projecting revenue growth and improved margins, which has boosted investor confidence and generated a bullish sentiment.
• Despite concerns raised by some analysts about weaker gross margins and potential pricing pressures, Dexcom's proactive approach to product development and leadership changes has outweighed these worries, leading to an increase in the stock price.

06.00.2026 - DXCM Stock was up 5.1%

• The bullish movement in DXCM stock today can be attributed to the unveiling of a new app feature by a competitor aimed at enhancing mealtime decisions for individuals with diabetes. This innovation in the diabetes management space may have positively influenced investor sentiment towards DexCom.
• The market may also be reacting to the detailed overview of DexCom's stock performance and financial data, showcasing its fundamental strength and role in continuous glucose monitoring systems.
• Additionally, the nuanced view on Dexcom's valuation and long-term growth prospects from top institutional shareholders and recent insider trades might have instilled confidence in investors, contributing to the bullish momentum.

22.00.2026 - DXCM Stock was up 4.4%

• Despite challenges like a recent Class 1 recall for some G7 receivers, Dexcom announced an impressive Q3 2024 revenue growth of 22% year-over-year, amounting to $1.2 billion. This growth was fueled by expanding its customer base and launching new products such as the Stelo for non-insulin users.
• Analysts have a positive consensus on DXCM, rating it as a "Strong Buy" with an average price target of $85.00, indicating a potential upside of 22.6%. This positive sentiment stems from the company's strong performance in the healthcare industry and its ability to capture the growing market of diabetes patients embracing CGM technology.
• The rise in DXCM's stock price today is attributed to its strong financial performance, favorable analyst ratings, and the overall growth opportunities in the healthcare sector, particularly in patient monitoring.
• Institutional ownership of DXCM remains high at 97.75%, despite Fisher Funds Management LTD selling a portion of its stake, showcasing ongoing confidence in the company's future prospects and market position.

27.02.2026 - DXCM Stock was down 6.2%

• The amendment filed by a major institutional investor, stating it no longer beneficially owns any shares of DXCM, might have raised concerns among investors, leading to a sell-off.
• DXCM underperforming compared to its competitors and the broader market could have contributed to the bearish movement, as investors may have shifted their focus to other more promising opportunities.
• Despite Dexcom's impressive Q4 earnings and institutional buying interest, the overall negative sentiment in the market, coupled with concerns about the company's future growth prospects amidst competition and regulatory hurdles, likely weighed down on the stock price.

27.02.2026 - DXCM Stock was down 5.9%

• DXCM's stock price saw a considerable decrease in line with major indices like the S&P 500 and Dow Jones Industrial Average. This decline was influenced by rising uncertainties related to the U.S.-Iran conflict and impending policy decisions by the Trump administration.
• Despite DXCM exhibiting robust Year-over-Year EBITDA Growth of 52.52% and being deemed significantly undervalued, some investors may have exercised caution due to certain warning signals identified in the analysis.
• The recent disclosure by Vanguard Group, revealing no holdings of DXCM common stock subsequent to an internal reshuffling, may have further dampened investor sentiment towards the company.
• DXCM's underperformance in comparison to its competitors on Thursday and the conclusion of a two-day positive streak could have also played a role in the stock's downward trajectory, particularly amid the widespread market declines observed.

05.02.2026 - DXCM Stock was down 1.7%

• DexCom's stock witnessed a downturn despite surpassing analyst projections with its quarterly earnings. This drop may be linked to significant sell-offs made by Fisher Asset Management LLC.
• While institutional holdings from leading firms like Vanguard, MFS, and Picton Mahoney Asset Management saw an increase, it was insufficient to counterbalance the impact of Fisher Asset Management's divestment, leading to a negative trend in the stock price.
• Analysts have maintained a "Moderate Buy" consensus on DexCom, with an average target price of $85.18. This suggests continued faith in the company's prospects, even amidst ongoing market fluctuations influenced by institutional trading.

13.01.2026 - DXCM Stock was up 8.3%

• DexCom's stock price saw an 8.4% increase following the company's surpassing of Q4 earnings and revenue expectations, demonstrating robust financial performance and market confidence.
• Analysts have revised upwards their price objectives for DXCM, with targets raised to $85.05 by Mizuho and $90.00 by BTIG, indicating positive sentiment and potential for further advancement.
• The successful launch of innovative products like the DexCom G7 15-day system and DexCom Smart Basal, alongside opportunities for expansion into international markets, have contributed to the positive market trend.
• Although encountering short-term challenges like trading below moving averages and a high P/E ratio, DexCom's strong financial position, optimistic market growth outlook, and upcoming catalysts point towards a bright future for the company.

13.01.2026 - DXCM Stock was up 7.4%

• Despite DexCom's strong financial performance, including beating Q4 earnings and revenue estimates, the stock experienced a slight fall in after-hours trading. This could be due to profit-taking by investors after a recent surge in the stock price.
• The anticipation of expanded Medicare coverage for CGMs for Type 2 diabetes patients is a positive development for DexCom, indicating potential growth opportunities in a new market segment.
• The company's 2026 revenue forecast falling slightly below analysts' expectations may have contributed to some investor uncertainty, leading to the mixed market movement despite the positive earnings beat.
• Overall, the bullish movement in DexCom's stock today could be attributed to the company's strong financial performance, anticipation of expanded market opportunities, and positive analyst reactions, despite some lingering concerns about revenue forecasts.

13.01.2026 - DXCM Stock was up 5.2%

• The positive movement in DXCM stock today is driven by the impressive Q4 performance and optimistic outlook shared during the earnings call.
• Mizuho's increase in price targets and "Buy" ratings maintained by Wells Fargo and Stifel reflect favorable analyst sentiment and confidence in the company's future growth potential.
• Despite some immediate challenges like trading below moving averages and a high P/E ratio, investor confidence remains high due to DXCM's innovative products like the DexCom G7 15-day system and DexCom Smart Basal, as well as substantial international expansion opportunities.
• Anticipated catalysts in 2026, such as potential Medicare coverage and new product launches, contribute to the positive market sentiment surrounding DXCM, positioning it as a top choice in the diabetes sector and potentially undervalued per InvestingPro's Fair Value assessment.